2008
DOI: 10.1080/10915810802368196 View full text |Buy / Rent full text
|
|

Abstract: Monoclonal antibodies directed against tumor necrosis factor alpha (TNFalpha) are currently employed in the treatment of various immune-mediated diseases. These studies were designed to evaluate potential effects of anti-TNFalpha treatment in mice during pregnancy and lactation on the development of the immune system in the F1 generation. Pregnant CD-1 mice were treated with vehicle or with 10 or 40 mg/kg of an anti-mouse TNFalpha monoclonal antibody (mAb) (cV1q) on days 6, 12, and 18 of gestation and on days … Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
1
1
1
2
13
0

Year Published

2009
2009
2013
2013

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

2
13
0
Order By: Relevance
“…Interestingly, however, the tumor-induced increase in spleen weight (see above), was partially, although significantly, reversed, suggesting a biological effect of the TNF antibody on this organ. A similar observation was made in a previous study in which the same TNF-neutralizing antibody was shown to partially block the increase in spleen weight resulting from immunization with sheep RBC (23).…”
Section: Mammary Tumor Growth Is Inhibited In Mice Treated With a Tnfsupporting
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Interestingly, however, the tumor-induced increase in spleen weight (see above), was partially, although significantly, reversed, suggesting a biological effect of the TNF antibody on this organ. A similar observation was made in a previous study in which the same TNF-neutralizing antibody was shown to partially block the increase in spleen weight resulting from immunization with sheep RBC (23).…”
Section: Mammary Tumor Growth Is Inhibited In Mice Treated With a Tnfsupporting
“…cV1q is an antimouse TNF-α antibody which is a chimeric (rat variable regions, mouse constant regions) monoclonal antibody (23). The properties of cV1q with regard to specificity, affinity, and neutralization of murine TNF are analogous to those seen for the human TNF-specific antibody, infliximab (Remicade).…”
Section: Effect Of Tnf Status On Carcinogen Sensitivity Of Mammary Glmentioning
“…The potential short-term and long-term effects of infliximab exposure on the newborn are largely unknown, but experimental data in mice [23] and macaques [24] suggest that anti-TNF-α antibody treatment during pregnancy and lactation has minor or no effect on the development or maturation of the immune system in the offspring.…”
Section: Discussionmentioning
“…Adverse events associated with therapeutic mAbs are often related specifically to binding of a target moiety or to modifying an intended biochemical pathway (Kamba and McDonald 2007). Recently, several publications have documented nontarget-related effects of mAbs on peripheral blood cells (Martin et al 2008;Rudmann et al 2011;Adis, 2002;Santostefano et al 2012). Each of these examples has shown unique characteristics with respect to cells affected, affinity of the unintended Purified monocytes were incubated with CMFDAlabeled platelets and isotype control, positive control W6/32, and mAbY.1 at 3 concentrations for 6 hr.…”
Section: Thrombocytopenia and Rbc Decreases Were Notmentioning
“…Putative offtarget effects presenting as decreases in platelets were observed in cynomolgus monkeys during nonclinical in vivo testing of mAbs against IL-13, immunoglobulin (Ig)E, an unspecified cell-based target, and in rats dosed with a mAb against sclerostin (Adis, 2002;Martin et al 2008;Rudmann et al 2011;Santostefano et al 2012).…”
Section: Introductionmentioning